BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 32890967)

  • 1. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
    Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
    Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Sallenave JM; Guillot L
    Front Immunol; 2020; 11():1229. PubMed ID: 32574272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
    Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
    Grimes JM; Grimes KV
    J Mol Cell Cardiol; 2020 Jul; 144():63-65. PubMed ID: 32422320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing existing drugs for COVID-19: an endocrinology perspective.
    Cadegiani FA
    BMC Endocr Disord; 2020 Sep; 20(1):149. PubMed ID: 32993622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Proteases for Treating COVID-19.
    Luan B; Huynh T; Cheng X; Lan G; Wang HR
    J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
    Brufsky A
    J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global treatments for coronaviruses including COVID-19.
    Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
    J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.
    Vankadari N
    Int J Antimicrob Agents; 2020 Aug; 56(2):105998. PubMed ID: 32360231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.